Skip to Content

Aventis discloses details of most extensive research program on Allegra

BRIDGEWATER, N.J., November 27, 2002 -- Aventis released new information on the most comprehensive research program to date to study prescription seasonal allergy antihistamine Allegra (fexofenadine HCl). Aventis is working to expand its range of new formulations and potential uses for Allegra.

"Clinical research is the cornerstone of Aventis' commitment to enhancing the quality of life of patients," said Dr. Francois Nader, Senior Vice President, Medical Affairs, North America, Aventis Pharmaceuticals. "The clinical trials underway for Allegra demonstrate our support of continued pharmaceutical research to expand our understanding of respiratory conditions."

Trials have just begun in the United States to investigate the use of Allegra in wide range of disease states, including year round (perennial) allergies and indoor allergies. Aventis also is evaluating new formulations that offer greater patient convenience, including an orally disintegrating tablet and a once-daily version of Allegra-D.

A key focus for Aventis is the link between asthma and allergic rhinitis. Clinical trials are already underway, looking at Allegra as a potential treatment for mild to moderate allergic asthma.

According to a long-term Brown University study published in the Annals of Allergy, Asthma and Immunology (Vol. 84 No. 5, 2000), individuals with allergic rhinitis are about three times more likely to develop asthma, underscoring the need for proper diagnosis and treatment by a supervising physician. This was a 23-year follow-up study of 1,601 college students with asthma and allergic rhinitis.

"Allergies are a serious medical condition requiring the intervention of a medical expert for proper diagnosis," Dr. Nader said. "Because of the implications of improper treatment, this condition demands careful attention from patients, employers and insurance companies."

Allegra is a prescription antihistamine indicated for the treatment of symptoms of seasonal allergic rhinitis and chronic idiopathic uticaria (CIU). Allegra-D (fexofenadine HCl 60 mg and pseudoephedrine 120 mg) extended release tablets are indicated for the relief of symptoms of seasonal allergies including congestion. Allegra has been proven safe and effective and has more than 4 billion patient days of therapy worldwide. Studies show that Allegra offers powerful, fast-acting relief at just 60 minutes, and is non-impairing while driving and non-sedating.

Allegra is available by prescription only, and seasonal allergy sufferers should consult their physician or healthcare professional with questions. Side effects with Allegra 180 mg once daily are low and may include headache, cold or back pain. Side effects with Allegra 60 mg for seasonal allergies are low; less than 3% of people experience cold or flu, nausea, menstrual pain or drowsiness. Side effects with Allegra 60 mg for hives are low and may include back pain, sinusitis, dizziness and drowsiness. Side effects with Allegra 30 mg are low and may include headache, cold, coughing, or accidental injury.

For product information about Allegra or Allegra-D, visit
Full prescribing information is available by visiting the Aventis Pharmaceuticals U.S. Web site at

Posted: November 2002